Quest Diagnostics Incorporated (DGX) fair value analysis

S&P 500 · Updated 2026-09-07

Quest Diagnostics is a clinical laboratory services company that provides diagnostic testing, drug screening, and health and wellness services to patients, employers, hospitals, and physicians. The company operates through a network of patient service centers and laboratory facilities across the United States and select international markets.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, DGX is trading at more than a 25% premium to estimated fair value.

DGX currently ranks #103 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $237.14
Sector: Healthcare
12-month range: $173.79–$236.22

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C
Leverage: Moderate
Margin trend: Stable
Revenue growth: Modest
RSI zone: Neutral
52-week position: The top quarter of its range
DCF cross-check: Overvalued

What our data shows for DGX

Our model validated 17 trailing price-to-earnings windows for DGX, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $173.79–$236.22.
The 14-day relative strength index sits at a neutral 48.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for DGX
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent DGX news

TickrTrends' derived news-sentiment signal for DGX is currently mixed, computed from recent coverage.

Quest Diagnostics Stock: Is Wall Street Bullish or Bearish? (finance.yahoo.com, 2026-08-25)
TickrTrends take: Quest Diagnostics operates in the Healthcare sector and is currently assessed as overvalued according to TickrTrends' derived valuation metrics. Given this overvalued status, investors focused on valuation should monitor whether Wall Street's sentiment toward the stock reflects concerns about its current pricing, or conversely, whether bullish analyst views might indicate confidence that the company can justify its valuation through future performance. The divergence between valuation assessment and analyst sentiment could signal either a potential correction risk or an opportunity for those with conviction in the company's growth trajectory.
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? (zacks.com, 2026-08-21)
TickrTrends take: Quest Diagnostics has reached its 52 week high, which presents a valuation consideration for investors monitoring the Healthcare sector stock. Given TickrTrends' current assessment that DGX is overvalued, the continuation of this upward price movement would likely increase the gap between the stock's current market price and its derived valuation metrics. Investors focused on valuation should observe whether the stock's momentum sustains or whether mean reversion occurs as valuations become more stretched.
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out? (zacks.com, 2026-07-24)
TickrTrends take: Quest Diagnostics has reached its 52-week high, which TickrTrends currently assesses as overvalued based on its derived valuation metrics. For investors focused on valuation fundamentals, the combination of a stock at elevated price levels and an overvalued rating suggests caution about entry points or holding positions. Monitoring whether the company's Healthcare sector fundamentals can support these elevated prices will be important for determining if the overvaluation represents a temporary or sustained condition.

What people are saying

Follow the DGX conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for DGX shifted toward a more cautious outlook this week, with the DCF cross-check band moving from fairly valued to overvalued territory. The momentum indicator, which had registered at B, declined to none, suggesting weakening price momentum alongside the valuation deterioration. These concurrent shifts reinforce the current overvalued assessment for the healthcare sector company.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is DGX stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), DGX is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is DGX's TickrTrends verdict?

DGX's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does DGX compare to other Healthcare stocks?

DGX ranks #103 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is DGX overbought or oversold?

DGX's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

DGX vs ACAD · DGX vs ALKS · DGX vs AMGN · DGX vs BMY · DGX vs CDNA